[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals International plc (KNSA), exercised 42,000 previously granted options at an exercise price of $17.92 on 09/29/2025, acquiring 42,000 Class A ordinary shares. The option is fully vested and exercisable and has an expiration date of 03/03/2029.

The reporting person sold 42,000 Class A ordinary shares the same day under a 10b5-1 trading plan established April 29, 2024, at a weighted-average sales price of $38.33 per share (trades ranged $37.92–$38.85). After these transactions the reporting person beneficially owned 34,552 Class A ordinary shares.

Positive

• Exercise of vested options indicates compensation converted to equity under standard terms
• Sale executed under a 10b5-1 plan, signaling a pre-established, rule-compliant trading program

Negative

• Insider reduced holdings to 34,552 Class A ordinary shares after the transactions
• Sale involved multiple trades at prices up to $38.85, which may indicate partial execution over price range

Insights

Corporate Governance Expert

TL;DR: Insider exercised vested options and simultaneously sold equivalent shares under a pre-established 10b5-1 plan; routine, non-surprising disclosure.

The Form 4 shows a common insider liquidity event where newly exercised option shares funded sales executed under a 10b5-1 plan. The filer exercised 42,000 options at $17.92 and sold 42,000 shares at a weighted-average of $38.33, reducing holdings to 34,552 shares. Because the sale was executed pursuant to a documented 10b5-1 plan and the option was fully vested, this disclosure aligns with standard governance and insider-trading transparency practices. There is no indication of unusual timing or undisclosed related-party transactions in the filing.

Securities Analyst

TL;DR: Transaction indicates insider monetization at ~ $38.33 per share after exercising at $17.92; informational but not materially market-moving.

The reporting shows exercise of 42,000 options at $17.92 and immediate disposition of 42,000 shares at an average price of $38.33, resulting in a gross spread before fees of roughly $20.41 per share on those shares. The sale was executed through a broker in multiple trades under a 10b5-1 plan. Post-transaction ownership of 34,552 shares is disclosed. For investors, this is a liquidity action by management rather than new strategic information about company operations or financial performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tessari Eben

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/29/2025		M(1)		42,000	A	$17.92	76,552	D
Class A Ordinary Share	09/29/2025		S(1)		42,000	D	$38.33(2)	34,552	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$17.92	09/29/2025		M(1)			42,000	(3)	03/03/2029	Class A Ordinary Share	42,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Tessari Eben report on the KNSA Form 4?

The filing reports exercise of 42,000 options at an exercise price of $17.92 and sale of 42,000 Class A ordinary shares at a weighted-average price of $38.33 on 09/29/2025.

Were the sales executed under a trading plan for KNSA insider Tessari Eben?

Yes. The sales were effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

How many KNSA shares does Tessari Eben own after the reported transactions?

Following the transactions, the reporting person beneficially owned 34,552 Class A ordinary shares.

Is the option exercised by Tessari Eben vested and when does it expire?

The option was reported as fully vested and exercisable with an expiration date of 03/03/2029.

What price range were the sold KNSA shares executed at?

The sales were executed in multiple trades at prices ranging between $37.92 and $38.85; the weighted-average sales price reported is $38.33.